Hye In Lim1,2,3, Y U Sun4,2, Qinghong Han4, Jun Yamamoto4,2, Robert M Hoffman1,2. 1. AntiCancer Inc, San Diego, CA, U.S.A.; vastprogress@naver.com all@anticancer.com. 2. Department of Surgery, University of California, San Diego, CA, U.S.A. 3. Department of Surgery, Chinjujeil Hospital, Jinju, Republic of Korea. 4. AntiCancer Inc, San Diego, CA, U.S.A.
Abstract
BACKGROUND/AIM: The aim of the present study was to identify effective drugs for a highly-aggressive liver-metastasis of triple-negative breast cancer (TNBC) in a patient-derived orthotopic xenograft (PDOX) mouse model. Drugs tested were oral recombinant methioninase (o-rMETase), low-dose eribulin and their combination. MATERIALS AND METHODS: Patient-derived TNBC was implanted in the liver of nude mice by surgical hepatic implantation. Two weeks after transplantation, 32 mice were randomized (n=8 per group) into a phosphate-buffered saline vehicle-control group; o-rMETase-treatment group (100 units, o-rMETase, oral, daily for 2 weeks); eribulin-treatment group (0.05 mg/kg intraperitoneally once per week for 2 weeks); or combination-treatment group (100 units r-METase, oral, daily for 2 weeks + 0.05 mg/kg eribulin intraperitoneally once per week for 2 weeks). RESULTS: After 2 weeks, the three treatment groups exhibited significantly-inhibited TNBC growth in the liver compared to the vehicle-control group (p≤0.05). CONCLUSION: o-rMETase and low-dose eribulin monotherapy and their combination were efficacious against the highly-aggressive TNBC PDOX growing in the liver. The TNBC PDOX model can be used to identify highly-effective drugs for therapy of TNBC with liver metastasis.
BACKGROUND/AIM: The aim of the present study was to identify effective drugs for a highly-aggressive liver-metastasis of triple-negative breast cancer (TNBC) in a patient-derived orthotopic xenograft (PDOX) mouse model. Drugs tested were oral recombinant methioninase (o-rMETase), low-dose eribulin and their combination. MATERIALS AND METHODS: Patient-derived TNBC was implanted in the liver of nude mice by surgical hepatic implantation. Two weeks after transplantation, 32 mice were randomized (n=8 per group) into a phosphate-buffered saline vehicle-control group; o-rMETase-treatment group (100 units, o-rMETase, oral, daily for 2 weeks); eribulin-treatment group (0.05 mg/kg intraperitoneally once per week for 2 weeks); or combination-treatment group (100 units r-METase, oral, daily for 2 weeks + 0.05 mg/kg eribulin intraperitoneally once per week for 2 weeks). RESULTS: After 2 weeks, the three treatment groups exhibited significantly-inhibited TNBC growth in the liver compared to the vehicle-control group (p≤0.05). CONCLUSION: o-rMETase and low-dose eribulin monotherapy and their combination were efficacious against the highly-aggressive TNBC PDOX growing in the liver. The TNBC PDOX model can be used to identify highly-effective drugs for therapy of TNBC with liver metastasis.
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Hye In Lim; Kazuyuki Hamada; Jun Yamamoto; Qinhong Han; Yuying Tan; Hee Jun Choi; Seok Jin Nam; Michael Bouvet; Robert M Hoffman Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Hye In Lim; Jun Yamamoto; Qinhong Han; Y U Sun; Hiroto Nishino; Yoshihiko Tashiro; Norihiko Sugisawa; Yuying Tan; Hee Jun Choi; Seok Jin Nam; Michael Bouvet; Robert M Hoffman Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Stacey L Borrego; Johannes Fahrmann; Jue Hou; Da-Wei Lin; Bruce J Tromberg; Oliver Fiehn; Peter Kaiser Journal: J Lipid Res Date: 2021-02-26 Impact factor: 5.922